BR112014021331A8 - Antagonistas do receptor do hormônio liberador de gonadotropina, composição farmacêutica compreendendo os mesmos e uso desses - Google Patents

Antagonistas do receptor do hormônio liberador de gonadotropina, composição farmacêutica compreendendo os mesmos e uso desses

Info

Publication number
BR112014021331A8
BR112014021331A8 BR112014021331A BR112014021331A BR112014021331A8 BR 112014021331 A8 BR112014021331 A8 BR 112014021331A8 BR 112014021331 A BR112014021331 A BR 112014021331A BR 112014021331 A BR112014021331 A BR 112014021331A BR 112014021331 A8 BR112014021331 A8 BR 112014021331A8
Authority
BR
Brazil
Prior art keywords
gonadotropin
pharmaceutical composition
receptor antagonists
hormone receptor
releasing hormone
Prior art date
Application number
BR112014021331A
Other languages
English (en)
Other versions
BR112014021331B1 (pt
BR112014021331A2 (pt
Inventor
Kim Seon-Mi
Kim Jae-Sun
Lee Minhee
Lee So-Young
Lee Bong-Yong
Ah Shin Young
Park Euisun
A Lee Jung
Han Min-Young
Ahn Jaeseung
Yoo Taekyung
Kim Hun-Taek
Original Assignee
Sk Chemicals Co Ltd
Tiumbio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Chemicals Co Ltd, Tiumbio Co Ltd filed Critical Sk Chemicals Co Ltd
Publication of BR112014021331A2 publication Critical patent/BR112014021331A2/pt
Publication of BR112014021331A8 publication Critical patent/BR112014021331A8/pt
Publication of BR112014021331B1 publication Critical patent/BR112014021331B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

ANTAGONISTAS DO RECEPTOR DO HORMÔNIO LIBERADOR DE GONADOTROPINA, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS MESMOS E USO DESSES. A presente invenção revela antagonistas do receptor do hormônio liberador de gonadotropina e uma composição farmacêutica compreendendo os mesmos, que pode ser útil para prevenir ou tratar uma doença relacionada a hormônios sexuais, tais como endometriose, amenorréia, menstruação irregular, mioma uterino, fibróides uterinas, doença ovariana policística, lúpus eritematoso, hipertricose, puberdade precoce, baixa estatura, acne, alopécia, neoplasmas gonodais esteróide dependentes, adenoma pituitário produtor de gonadotropina, apnéia do sono, síndrome do intestino irritável, síndrome pré-menstrual, hiperplasia prostática benigna, contracepção, e infertilidade, bem como doença de Alzheimer.
BR112014021331-3A 2012-02-28 2013-02-28 Antagonistas do receptor do hormônio liberador de gonadotropina, composição farmacêutica compreendendo os mesmos e uso desses BR112014021331B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20120020479 2012-02-28
KR10-2012-0020479 2012-02-28
PCT/KR2013/001660 WO2013129879A1 (en) 2012-02-28 2013-02-28 Gonadotropin releasing hormone receptor antagonists, method for the preparation thereof and pharmaceutical composition comprising the same

Publications (3)

Publication Number Publication Date
BR112014021331A2 BR112014021331A2 (pt) 2017-06-20
BR112014021331A8 true BR112014021331A8 (pt) 2017-10-10
BR112014021331B1 BR112014021331B1 (pt) 2020-12-15

Family

ID=49082998

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014021331-3A BR112014021331B1 (pt) 2012-02-28 2013-02-28 Antagonistas do receptor do hormônio liberador de gonadotropina, composição farmacêutica compreendendo os mesmos e uso desses

Country Status (11)

Country Link
US (1) US9481684B2 (pt)
EP (1) EP2820021B1 (pt)
JP (1) JP6209171B2 (pt)
KR (1) KR101495260B1 (pt)
CN (2) CN104136441B (pt)
AU (1) AU2013226661B2 (pt)
BR (1) BR112014021331B1 (pt)
CA (1) CA2865547C (pt)
ES (1) ES2613856T3 (pt)
MX (1) MX357841B (pt)
WO (1) WO2013129879A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016005142A (es) 2013-10-30 2016-10-28 Shanghai hengrui pharmaceutical co ltd Derivados de pirazolopirimidona o pirrolotriazona, metodo y preparacion de los mismos y aplicaciones farmaceuticas de los mismos.
UA126345C2 (uk) * 2017-07-28 2022-09-21 Джянгсу Хенгруй Медісін Ко., Лтд. Спосіб отримання похідної гетероарилпіримідону та гетероарилпіримідонової проміжної похідної сполуки
KR101973074B1 (ko) * 2018-11-30 2019-04-26 주식회사 티움바이오 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물
CN109651265A (zh) * 2019-02-16 2019-04-19 安徽诺全药业有限公司 一种Elagolix的制备方法
CN112955181A (zh) 2019-03-26 2021-06-11 新型医药公司 一种长效脂肪酸缀合的GnRH衍生物及含其的药物组合物
KR20210155350A (ko) 2020-06-15 2021-12-22 한상왕 녹차 추출물 및 비타민 d3를 유효성분으로 포함하는 자궁근종 개선용 조성물
CN115124545B (zh) * 2022-08-31 2023-01-03 南京远淑医药科技有限公司 一种促性腺激素释放激素受体拮抗剂中间体的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2163325A1 (en) 1994-11-21 1996-05-22 Kaneyoshi Kato Amine compounds, their production and use
US6156772A (en) * 1997-06-05 2000-12-05 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
TWI225863B (en) * 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
WO2001029044A1 (en) * 1999-10-15 2001-04-26 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
EP1412363A1 (en) * 2001-08-02 2004-04-28 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists
FR2833948B1 (fr) * 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
JP2005538064A (ja) 2002-06-13 2005-12-15 ファイザー・インク 非ペプチドＧｎＲＨ剤、医薬組成物、およびそれらの使用方法
BRPI0613643A2 (pt) * 2005-07-22 2012-11-06 Takeda Pharmaceutical inibidor de ovulação prematura, método de inibir ovulação prematura e uso de um composto
JP5757956B2 (ja) * 2009-11-20 2015-08-05 エスケー ケミカルス シーオー．， エルティーディー．Ｓｋ Ｃｈｅｍｉｃａｌｓ Ｃｏ．， Ｌｔｄ． ゴナドトロピン放出ホルモン受容体拮抗剤、その製造方法及びそれを含む医薬組成物

Also Published As

Publication number Publication date
AU2013226661A1 (en) 2014-10-16
KR101495260B1 (ko) 2015-02-26
BR112014021331B1 (pt) 2020-12-15
KR20130102002A (ko) 2013-09-16
US9481684B2 (en) 2016-11-01
CN105732649A (zh) 2016-07-06
JP2015510868A (ja) 2015-04-13
CA2865547C (en) 2020-03-10
ES2613856T3 (es) 2017-05-26
CN104136441B (zh) 2016-09-28
CN104136441A (zh) 2014-11-05
WO2013129879A1 (en) 2013-09-06
BR112014021331A2 (pt) 2017-06-20
EP2820021A1 (en) 2015-01-07
CA2865547A1 (en) 2013-09-06
US20150166558A1 (en) 2015-06-18
EP2820021B1 (en) 2016-11-30
CN105732649B (zh) 2019-02-05
MX357841B (es) 2018-07-26
JP6209171B2 (ja) 2017-10-04
EP2820021A4 (en) 2015-10-21
AU2013226661B2 (en) 2017-08-31
MX2014010345A (es) 2014-11-14

Similar Documents

Publication Publication Date Title
BR112014021331A8 (pt) Antagonistas do receptor do hormônio liberador de gonadotropina, composição farmacêutica compreendendo os mesmos e uso desses
CL2007003266A1 (es) Compuestos derivados de progesterona, antagonistas del receptor de progesterona; composicion farmaceutica; y uso para el tratamiento de endometriosis, miomas o tumores dependientes de hormonas.
GT201500206A (es) Modulador del receptor de andrógeno y usos de este
BR112015025238A2 (pt) composição contendo trifluoroetileno
NO20070294L (no) Gonadotropinfrigjorende hormon reseptor antagonister
EA202090461A1 (ru) Фармацевтические препараты для лечения эндометриоза, миомы матки, синдрома поликистоза яичников или аденомиоза
CY1118657T1 (el) 6((s)-1-{1-[5-(2-yδpoξy-aiθoξy)-πypiδin-2-yλo]-1η-πypazoλ-3-yλo}-aiθyλo)-3η-1,3-βενζοθειαζολ-2-ονη) ως ενας εξαρτωμενος απο tarp γ8 ανταγωνιστης υποδοχεα αμρα
WO2011098436A3 (de) Progesteronrezeptorantagonisten
MX2016005142A (es) Derivados de pirazolopirimidona o pirrolotriazona, metodo y preparacion de los mismos y aplicaciones farmaceuticas de los mismos.
UA83928C2 (ru) Производное пропан-1,3-диона или его соль
PE20141699A1 (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
WO2009134725A3 (en) Monomethylamine progesteron antagonists such as cdb-4453 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc
ECSP088546A (es) Alquilsulfonamida-quinoleínas
NZ602525A (en) Compositions and methods for non-toxic delivery of antiprogestins
EP1488807A4 (en) MEDICAMENTS FOR TREATING SEXUAL HORMONE DEPENDENT DISEASE
MX2009009514A (es) Heterociclos sulfonilados utiles para la modulacion del receptor de progesterona.
TR201900954T4 (tr) Progesteron reseptör antagonisti dozaj formu.
PH12015502318A1 (en) Spiroindoline derivatives for use as gonadotropin-releasing hormone receptor antagonists
AR096905A1 (es) Derivados de espiroindolina y composiciones farmacéuticas de los mismos
Jinling Sidelights of CAFIU Delegation's Visit to Japan and Thailand
Suh et al. The emotional sensibility estimation system for drum washer
Yasukochi et al. Corrigendum to" Sulfasalazine alleviates neuropathic pain hypersensitivity in mice through inhibition of SGK-1 in the spinal cord"[Biochem. Pharmacol. 185 (2021) 114411]
Tsai et al. Single Molecule Characterization of Conjugated Oligomers Formed through Radical Cyclization at a Surface
Jo et al. The Evaluation of Technology for Temperature Reduction of Mixing & Compaction for Polymer Modified Asphalt
Ezerski et al. Mutation Induced Conformational Change In CaMKII Peptide Alters Binding Affinity to CaM Through Alternate Binding Site

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: TIUMBIO CO., LTD (KR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/02/2013, OBSERVADAS AS CONDICOES LEGAIS.